NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice GuidelinesGeorge D. Demetri, John Zalcberg, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2007Cited by 636
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutantsMaria Dêbiec‐Rychter, Peter Marynen|Gastroenterology|2005Cited by 494
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsPiotr Rutkowski, Scott M. Schuetze, M. van Glabbeke et al.|Journal of Clinical Oncology|2010Cited by 401
Identification of a Disease-Defining Gene Fusion in Epithelioid HemangioendotheliomaMunir R. Tanas, Brian P. Rubin, Mark Gerstein et al.|Science Translational Medicine|2011Cited by 401
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2012Cited by 69